John Wald, MD
Neurology · Jackson, MINPI 1275627366
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $392,161 of the $433,997 with a category attached, or 90.4%. 27 manufacturers reported payments, led by AbbVie at 54.6% of the total. Reporting peaked in 2021 at $109,723 and has fallen 52.3% since, to $52,284 in 2025. Among neurology clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 858 payments — averaging $505.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$237K
- Teva Pharmaceuticals USA, Inc.$114K
- Amgen$44K
- Biohaven Pharmaceuticals, Inc.$16K
- Sanofi$15K
- Pfizer$5K
- plus $3K from 21 others
Across 7 payments — averaging $1535.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$10K
- Novartis$1K
What the payments were for
- Consulting fees$7,4102%
- Speaking & faculty fees$392,16190%
- Travel & lodging$18,2324%
- Food & beverage$15,4374%
- Education$7580%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 365 | $237,155 |
| Teva Pharmaceuticals USA, Inc. | 238 | $113,817 |
| Amgen | 81 | $44,228 |
| Biohaven Pharmaceuticals, Inc. | 30 | $16,028 |
| Sanofi | 50 | $14,505 |
| Pfizer | 7 | $4,891 |
| Banner Life Sciences, LLC | 1 | $900 |
| Biogen | 10 | $605 |
| Novartis | 15 | $444 |
| UCB, Inc. | 7 | $240 |
| Johnson & Johnson | 21 | $228 |
| Adamas Pharmaceuticals, Inc. | 10 | $227 |
| Abbott | 1 | $153 |
| Kyowa Kirin, Inc. | 2 | $146 |
| Genentech USA, Inc. | 2 | $136 |
| Supernus Pharmaceuticals, Inc. | 3 | $52 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $38 |
| EMD Serono, Inc. | 2 | $31 |
| Avion Pharmaceuticals | 1 | $27 |
| Bristol Myers Squibb | 2 | $27 |
| Neurocrine Biosciences, Inc. | 2 | $26 |
| Neurelis, Inc. | 2 | $25 |
| Eisai Inc. | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Acorda Therapeutics, Inc | 1 | $14 |
| Acadia Pharmaceuticals Inc | 1 | $12 |
| CSL Behring | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BOTOX$112,782
- UBRELVY$105,938
- Austedo XR$44,151
- AIMOVIG$43,355
- AJOVY$36,577
- AUSTEDO$28,849
- NURTEC ODT$20,396
- QULIPTA$17,684
- AUBAGIO$13,240
- Bafiertam$900
- TYSABRI$450
- AMPLATZER Occluders$153
- OCREVUS$126
- MAYZENT$125
- Nayzilam$125
- BOTOX COSMETIC$102
- GOCOVRI$101
- KESIMPTA$101
How this compares
$433,997 in reported general payments places this provider in the 95th percentile of 652 neurology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 36 | $223,026 |
| Austedo XrDeutetrabenazine | 15 | $158,423 |
| UbrelvyUbrogepant | 142 | $153,698 |
| Nurtec OdtRimegepant Sulfate | 100 | $128,697 |
| Aimovig AutoinjectorErenumab-Aooe | 105 | $103,975 |
| Tetrabenazine | 11 | $58,875 |
| Glatiramer Acetate | 13 | $41,177 |
| Ajovy SyringeFremanezumab-Vfrm | 38 | $39,109 |
| Teriflunomide | 42 | $33,401 |
| QuliptaAtogepant | 21 | $23,772 |
| Emgality PenGalcanezumab-Gnlm | 29 | $22,929 |
| BriviactBrivaracetam | 13 | $18,098 |
| Sumatriptan Succinate | 129 | $17,805 |
| Levetiracetam | 304 | $12,962 |
| Gabapentin | 515 | $10,557 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $113,817 | $381,44851 claims |
| AbbVieUbrelvy, Qulipta | $237,155 | $177,469163 claims |
| PfizerNurtec Odt | $4,891 | $128,697100 claims |
| UCB, Inc.Briviact | $240 | $18,09813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 652 neurology providers in Michigan.
Other neurology in Jackson
- Aaron EllenbogenFarmington Hills$1.6M
- Matthew HoltzmanWayne$1.4M
- Richard TroschFarmington Hills$1.2M
- Wade CooperAnn Arbor$991K
- Bisena BulicaDetroit$900K
- Julie BurnhamMount Clemens$836K
- Amit MasihOkemos$785K
- Martin BelkinFarmington Hills$712K
- Robert PaceOwosso$693K
- Rosemarie WalchOwosso$563K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.